High farnesoid X receptor expression predicts favorable clinical outcomes in PD‑L1<sup>low/negative</sup> non‑small cell lung cancer patients receiving anti‑PD‑1‑based chemo‑immunotherapy

Wang,Lina; Xu,Xiaolong; Shang,Bin; Sun,Jian; Liang,Bin; Wang,Xingguang; You,Wenjie; Jiang,Shujuan

doi:10.3892/ijo.2022.5330

High farnesoid X receptor expression predicts favorable clinical outcomes in PD‑L1^low/negative non‑small cell lung cancer patients receiving anti‑PD‑1‑based chemo‑immunotherapy

Authors:
- Lina Wang
- Xiaolong Xu
- Bin Shang
- Jian Sun
- Bin Liang
- Xingguang Wang
- Wenjie You
- Shujuan Jiang
View Affiliations

Affiliations: Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250021, P.R. China, Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, P.R. China
Published online on: February 23, 2022 https://doi.org/10.3892/ijo.2022.5330
Article Number: 40
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anti‑programmed death‑1 (PD‑1)/programmed death‑ligand 1 (PD‑L1)‑directed immunotherapy has revolutionized the treatment of advanced non‑small cell lung cancer (NSCLC). However, predictive biomarkers are still lacking, particularly in identifying PD‑L1^low/negative patients who will benefit from immunotherapy. It was previously reported that farnesoid X receptor (FXR) downregulated PD‑L1 expression in NSCLC, and that FXR^highPD‑L1^low mouse Lewis lung carcinoma tumors showed an increased susceptibility to PD‑1 blockade compared with mock tumors. At present, whether the FXR^highPD‑L1^low phenotype predicts clinical response to immunotherapy in patients with NSCLC remains unclear. Herein, a retrospective study was conducted to examine the expression levels of FXR, PD‑L1 and CD8⁺ T cells by immunohistochemistry in a cohort of 149 patients with NSCLC receiving anti‑PD‑1‑based chemo‑immunotherapy. The results revealed that high FXR and PD‑L1 expression levels were associated with higher objective response rates (ORR) in all patients. High PD‑L1 expression also indicated superior progression‑free survival (PFS). Interestingly, an inverse correlation was identified between FXR and PD‑L1 expression in specimens with NSCLC. Subgroup analysis revealed that high FXR expression was associated with a higher ORR, as well as longer PFS and overall survival (OS) in PD‑L1^low patients. Cox multivariate analysis revealed that high FXR expression was an independent predictor for PFS and OS in PD‑L1^low patients. Tumor microenvironment evaluation revealed a statistically significant decrease of infiltrating CD8⁺ T cells in FXR^high specimens with NSCLC. Overall, the present study proposed an FXR^highPD‑L1^low signature as a candidate predictor of response to anti‑PD‑1‑based chemo‑immunotherapy in PD‑L1^low/negative patients with NSCLC, providing evidence that could be used to broaden the patients benefitting from immunotherapy.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Duma N, Santana-Davila R and Molina JR: Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 94:1623–1640. 2019. View Article : Google Scholar : PubMed/NCBI
3	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
4	Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al: Pembrolizumab for the treatment of non-small-cell lung cancer. New Engl J Med. 372:2018–2028. 2015. View Article : Google Scholar : PubMed/NCBI
5	Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. New Engl J Med. 378:2078–2092. 2018. View Article : Google Scholar : PubMed/NCBI
6	Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. New Engl J Med. 373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
7	Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. New Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
8	Qin S, Xu L, Yi M, Yu S, Wu K and Luo S: Novel immune checkpoint targets: Moving beyond PD-1 and CTLA-4. Mol Cancer. 18:1552019. View Article : Google Scholar : PubMed/NCBI
9	Postow MA, Sidlow R and Hellmann MD: Immune-related adverse events associated with immune checkpoint blockade. New Engl J Med. 378:158–168. 2018. View Article : Google Scholar : PubMed/NCBI
10	Postow MA, Callahan MK and Wolchok JD: Immune checkpoint blockade in cancer therapy. J Clin Oncol. 33:1974–1982. 2015. View Article : Google Scholar : PubMed/NCBI
11	Shukuya T and Carbone DP: Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer. J Thorac Oncol. 11:976–988. 2016. View Article : Google Scholar : PubMed/NCBI
12	Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. New Engl J Med. 375:1823–1833. 2016. View Article : Google Scholar : PubMed/NCBI
13	Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S, et al: Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. New Engl J Med. 383:1328–1339. 2020. View Article : Google Scholar : PubMed/NCBI
14	Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, et al: Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol. 36:633–641. 2018. View Article : Google Scholar : PubMed/NCBI
15	Shirasawa M, Yoshida T, Shimoda Y, Takayanagi D, Shiraishi K, Kubo T, Mitani S, Matsumoto Y, Masuda K, Shinno Y, et al: Differential immune-related microenvironment determines programmed cell death protein-1/programmed death-ligand 1 blockade efficacy in patients with advanced NSCLC. J Thorac Oncol. 16:2078–2090. 2021. View Article : Google Scholar : PubMed/NCBI
16	Mansfield AS, Murphy SJ, Peikert T, Yi ES, Vasmatzis G, Wigle DA and Aubry MC: Heterogeneity of programmed cell death ligand 1 expression in multifocal lung cancer. Clin Cancer Res. 22:2177–2182. 2016. View Article : Google Scholar
17	Sacher AG and Gandhi L: Biomarkers for the clinical use of PD-1/PD-L1 inhibitors in non-small-cell lung cancer: A review. JAMA Oncol. 2:1217–1222. 2016. View Article : Google Scholar : PubMed/NCBI
18	Havel JJ, Chowell D and Chan TA: The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 19:133–150. 2019. View Article : Google Scholar : PubMed/NCBI
19	Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, et al: Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol. 34:4102–4109. 2016. View Article : Google Scholar : PubMed/NCBI
20	Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, Noonan DJ, Burka LT, McMorris T, Lamph WW, et al: Identification of a nuclear receptor that is activated by farnesol metabolites. Cell. 81:687–693. 1995. View Article : Google Scholar : PubMed/NCBI
21	Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J and Mangelsdorf DJ: Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell. 6:507–515. 2000. View Article : Google Scholar : PubMed/NCBI
22	Wang YD, Chen WD, Moore DD and Huang W: FXR: A metabolic regulator and cell protector. Cell Res. 18:1087–1095. 2008. View Article : Google Scholar : PubMed/NCBI
23	Yang F, Huang X, Yi T, Yen Y, Moore DD and Huang W: Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 67:863–867. 2007. View Article : Google Scholar : PubMed/NCBI
24	De Gottardi A, Touri F, Maurer CA, Perez A, Maurhofer O, Ventre G, Bentzen CL, Niesor EJ and Dufour JF: The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. Dig Dis Sci. 49:982–989. 2004. View Article : Google Scholar : PubMed/NCBI
25	Guan B, Li H, Yang Z, Hoque A and Xu X: Inhibition of farnesoid X receptor controls esophageal cancer cell growth in vitro and in nude mouse xenografts. Cancer. 119:1321–1329. 2013. View Article : Google Scholar : PubMed/NCBI
26	Journe F, Durbecq V, Chaboteaux C, Rouas G, Laurent G, Nonclercq D, Sotiriou C, Body JJ and Larsimont D: Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patients. Breast Cancer Res Treat. 115:523–535. 2009. View Article : Google Scholar
27	You W, Chen B, Liu X, Xue S, Qin H and Jiang H: Farnesoid X receptor, a novel proto-oncogene in non-small cell lung cancer, promotes tumor growth via directly transactivating CCND1. Sci Rep. 7:5912017. View Article : Google Scholar : PubMed/NCBI
28	You W, Li L, Sun D, Liu X, Xia Z, Xue S, Chen B, Qin H, Ai J and Jiang H: Farnesoid X receptor constructs an immunosuppressive microenvironment and sensitizes FXR^highPD-L1^low NSCLC to anti-PD-1 immunotherapy. Cancer Immunol Res. 7:990–1000. 2019. View Article : Google Scholar : PubMed/NCBI
29	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar
30	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
31	Cortellini A, Ricciuti B, Facchinetti F, Alessi JVM, Venkatraman D, Dall'Olio FG, Cravero P, Vaz VR, Ottaviani D, Majem M, et al: Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. Ann Oncol. 32:1391–1399. 2021. View Article : Google Scholar : PubMed/NCBI
32	Lantuejoul S, Sound-Tsao M, Cooper WA, Girard N, Hirsch FR, Roden AC, Lopez-Rios F, Jain D, Chou TY, Motoi N, et al: PD-L1 testing for lung cancer in 2019: Perspective from the IASLC pathology committee. J Thorac Oncol. 15:499–519. 2020. View Article : Google Scholar
33	Nakayama Y, Mimura K, Tamaki T, Shiraishi K, Kua LF, Koh V, Ohmori M, Kimura A, Inoue S, Okayama H, et al: Phospho-STAT1 expression as a potential biomarker for anti-PD-1/anti-PD-L1 immunotherapy for breast cancer. Int J Oncol. 54:2030–2038. 2019.PubMed/NCBI
34	Weigelin B, Krause M and Friedl P: Cytotoxic T lymphocyte migration and effector function in the tumor microenvironment. Immunol Lett. 138:19–21. 2011. View Article : Google Scholar : PubMed/NCBI
35	Blank C and Mackensen A: Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: An update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother. 56:739–745. 2007. View Article : Google Scholar
36	Lee JY, Lee KT, Lee JK, Lee KH, Jang KT, Heo JS, Choi SH, Kim Y and Rhee JC: Farnesoid X receptor, overexpressed in pancreatic cancer with lymph node metastasis promotes cell migration and invasion. Br J Cancer. 104:1027–1037. 2011. View Article : Google Scholar : PubMed/NCBI
37	Das A, Yaqoob U, Mehta D and Shah VH: FXR promotes endothelial cell motility through coordinated regulation of FAK and MMP-9. Arterioscler Thromb Vasc Biol. 29:562–570. 2009. View Article : Google Scholar : PubMed/NCBI
38	Wang W, Zhan M, Li Q, Chen W, Chu H, Huang Q, Hou Z, Man M and Wang J: FXR agonists enhance the sensitivity of biliary tract cancer cells to cisplatin via SHP dependent inhibition of Bcl-xL expression. Oncotarget. 7:34617–34629. 2016. View Article : Google Scholar : PubMed/NCBI
39	Guo J, Zheng J, Mu M, Chen Z, Xu Z, Zhao C, Yang K, Qin X, Sun X and Yu J: GW4064 enhances the chemosensitivity of colorectal cancer to oxaliplatin by inducing pyroptosis. Biochem Biophys Res Commun. 548:60–66. 2021. View Article : Google Scholar : PubMed/NCBI
40	Fusi A, Festino L, Botti G, Masucci G, Melero I, Lorigan P and Ascierto PA: PD-L1 expression as a potential predictive biomarker. Lancet Oncol. 16:1285–1287. 2015. View Article : Google Scholar : PubMed/NCBI
41	Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, et al: First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. New Engl J Med. 376:2415–2426. 2017. View Article : Google Scholar : PubMed/NCBI
42	Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515:563–567. 2014. View Article : Google Scholar : PubMed/NCBI
43	Kang DH, Park CK, Chung C, Oh IJ, Kim YC, Park D, Kim J, Kwon GC, Kwon I, Sun P, et al: Baseline serum interleukin-6 levels predict the response of patients with advanced non-small cell lung cancer to PD-1/PD-L1 inhibitors. Immune Netw. 20:e272020. View Article : Google Scholar : PubMed/NCBI
44	Botta GP, Kato S, Patel H, Fanta P, Lee S, Okamura R and Kurzrock R: SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. JCI Insight. 6:e1504532021. View Article : Google Scholar : PubMed/NCBI
45	Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, et al: IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 127:2930–2940. 2017. View Article : Google Scholar : PubMed/NCBI